Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 5A, 2008, Pages 1728-1738

  Sanganalmath, Santosh K ^a   Babick, Andrea P ^a   Barta, Judit ^a   Kumamoto, Hideo ^a   Takeda, Nobuakiya ^b   Dhalla, Naranjan S ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Jikei University Katsushika Medical Center   (Japan)

^c ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

Cardiac function; Gene expression; Heart failure; Myofibrillar proteins; SR function

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM; ISOPROTEIN; MESSENGER RNA; MYOSIN HEAVY CHAIN; PROTEIN;

ANIMAL; ARTICLE; CELL FRACTIONATION; GENE EXPRESSION REGULATION; GENETICS; HEART FAILURE; HEMODYNAMICS; MALE; METABOLISM; RAT; SARCOPLASMIC RETICULUM; SPRAGUE DAWLEY RAT; THROMBOCYTE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BLOOD PLATELETS; CALCIUM; GENE EXPRESSION REGULATION; HEART FAILURE; HEMODYNAMICS; MALE; MYOSIN HEAVY CHAINS; PROTEIN ISOFORMS; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SARCOPLASMIC RETICULUM; SUBCELLULAR FRACTIONS;

ANIMALIA; RATTUS;

EID: 54049149753     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00197.x     Document Type: Article

References (45)

1. Doggrell SA. Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin Investig Drugs. 2004 13 : 865 74.
2. Saini HK, Takeda N, Goyal RK, Kumamoto H, Arneja AS, Dhalla NS. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev. 2004 22 : 27 54.
3. Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sar-pogrelate. J Pharmacol Exp Therap. 1999 290 : 1475 81.
4. Saini HK, Sharma SK, Zahradka P, Kumamoto H, Takeda N, Dhalla NS. Attenuation of the serotonin-induced increase in intracellular calcium in rat aortic smooth muscle cells by sarpogrelate. Can J Physiol Pharmacol. 2003 81 : 1056 63.
5. Sharma SK, Del Rizzo DF, Zahradka P, Bhangu SK, Werner JP, Kumamoto H, Takeda N, Dhalla NS. Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells. Implications for long-term graft patency. Ann Thorac Surg. 2001 71 : 1856 64.
6. Brasil D, Temsah RM, Kumar K, Kumamoto H, Takeda N, Dhalla NS. Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. J Cardiovasc Pharmacol Ther. 2002 7 : 53 9.
7. Temsah RM, Kumamoto H, Takeda N, Dhalla NS. Sarpogrelate diminishes changes in energy stores and ultrastruc-ture of the ischemic-reperfused rat heart. Can J Physiol Pharmacol. 2001 79 : 761 7.
8. Nebigil CG, Maroteaux L. Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation. 2003 108 : 902 8.
9. Dhalla NS, Shao Q, Panagia V. Remodeling of cardiac membranes during the development of congestive heart failure. Heart Fail Rev. 1998 2 : 261 72.
10. Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Therapeut. 2006 11 : 31 45.
11. Sorkin EM, Markham A. Cilostazol. Drugs Aging. 1999 14 : 63 71.
12. Fujita M, Mizuno K, Ho M, Tsukahara R, Miyamoto A, Miki O, Ishii K, Miwa K. Sarpogrelate treatment reduces restenosis after coronary stenting. Am Heart J. 2003 145 : E16.
13. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999 100 : 21 6.
14. Wang J, Liu X, Ren B, Rupp H, Takeda N, Dhalla NS. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol. 2002 34 : 847 57.
15. 2+-transport and gene expression in congestive heart failure are modified by imidapril treatment. Am J Physiol Heart Circ Physiol. 2005 288 : H1674 82.
16. Saini HK, Shao Q, Musat S, Takeda N, Tappia PS, Dhalla NS. Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction. Br J Pharmacol. 2005 144 : 202 11.
17. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quanti-tation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989 2 : 358 67.
18. Wang J, Guo X, Dhalla NS. Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim Biophys Acta. 2004 1690 : 177 84.
19. Guo X, Chapman D, Dhalla NS. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losar-tan. Mol Cell Biochem. 2003 254 : 163 72.
20. Liu X, Takeda N, Dhalla NS. Troponin I phosphorylation in heart homogenate from diabetic rat. Biochim Biophys Acta. 1996 1316 : 78 84.
21. Wood MA, Hess ML. Long term oral therapy of congestive heart failure with phos-phodiesterase inhibitors. Am J Med Sci. 1989 297 : 105 13.
22. Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, Asakura M, Ogita H, Liao Y, Sakata Y, Ogai A, Fukushima T, Yamada J, Shinozaki Y, Kuzuya T, Mori H, Terada N, Hori M. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation. 2001 104 : 705 10.
23. Barta J, Sanganalmath SK, Sethi R, Kumamoto H, Takeda N, Edes I, Dhalla NS. Antithrombotic agents sarpogrelate and cilostazol differentially affect ventricular arrhythmias and survival in rats. Exp Clin Cardiol. 2006 11 : 246 (Abstract).
24. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, de Breyne B. Evaluation of the effect of phosphodi-esterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur. J Clin Pharmacol. 1994 46 : 191 6.
25. 2+ content in isolated failing and nonfailing human myocardium. Circ Res. 1999 85 : 38 46.
26. 2+ handling in heart failure. J Clin Invest. 2005 115 : 556 64.
27. 2+ homeostasis on contraction in post infarction myocytes. J Appl Physiol. 1999 86 : 943 50.
28. 2+ transport in congestive heart failure. Am J Physiol. 1992 262 : H868 74.
29. 2+/Calmodulin-dependent protein kinase is altered in heart failure. Circ Res. 2000 86 : 596 605.
30. Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date MO, Chrast J, Matsuzaki M, Peterson KL, Chien KR, Ross J Jr. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest. 2004 113 : 727 36.
31. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr., Kranias EG, Giles WR, Chien KR. Chronic phospholamban-sar- coplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999 99 : 313 22.
32. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res. 2000 86 : 616 21.
33. Kuschel M, Karczewski P, Hempel P, Schlegel WP, Krause EG, Bartel S. Ser16 prevails over Thr17 phospholamban phos-phorylation in the beta-adrenergic regulation of cardiac relaxation. Am J Physiol. 1999 276 : H1625 33.
34. 2+- sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res. 2003 57 : 37 47.
35. Bodor GS, Oakeley AE, Allen PD, Crimmins DL, Ladenson JH, Anderson PA. Troponin I phosphorylation in the normal and failing adult human heart. Circulation. 1997 96 : 1495 500.
36. Zhang R, Zhao J, Mandveno A, Potter JD. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res. 1995 76 : 1028 35.
37. Haddad F, Bodell PW, Qin AX, Giger JM, Baldwin KM. Role of antisense RNA in coordinating cardiac myosin heavy chain gene switching. J Biol Chem. 2003 278 : 37132 8.
38. VanBuren P, Harris DE, Alpert NR, Warshaw DM. Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res. 1995 77 : 439 44.
39. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res. 1987 61 : 539 47.
40. Ikeda K, Tojo K, Tokudome G, Hosoya T, Harada M, Nakao K. The effects of sar-pogrelate on cardiomyocyte hypertrophy. Life Sci. 2000 67 : 2991 6.
41. Brattelid T, Qvigstad E, Birkeland JA, Swift F, Bekkevold SV, Krobert KA, Sejersted OM, Skomedal T, Osnes JB, Levy FO, Sjaastad I. Serotonin responsiveness through 5-HT(2A) and 5-HT(4) receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle. J Mol Cell Cardiol. 2007 43 : 767 79.
42. Sweet CS, Ludden CT, Stabilito II, Emmert SE, Heyse JF. Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. Eur J Pharmacol. 1988 147 : 29 37.
43. Osadchii O, Norton G, Woodiwiss A. Inotropic responses to phosphodi-esterase inhibitors in cardiac hypertrophy in rats. Eur J Pharmacol. 2005 514 : 201 8.
44. Movsesian MA. PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J Card Fail. 2003 9 : 475 80.
45. Dhalla NS, Afzal A, Beamish RE, Naimark B, Takeda N, Nagano M. Pathophysiology of cardiac dysfunction in congestive heart failure. Can J Cardiol. 1993 9 : 873 87.